Focus: Impact Therapeutics is a Shanghai-based biotech company focused on small-molecule oncology and multi-indication therapeutics in early-to-mid stage development. The company is at Series C+ funding stage with a concentrated pipeline primarily in solid tumors and hematologic malignancies.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Hot — 117 jobs added in 30d
Net +104 (117 new, 13 removed). Aggressive expansion phase.
Impact Therapeutics offers oncology expertise and Asia market entry for biotech professionals, but lack of open positions and limited financial transparency present material hiring uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Impact Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Impact Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo